Log in or Sign up for Free to view tailored content for your specialty!
Dermatitis News
Baricitinib plus topical steroids improves atopic dermatitis symptoms
Combination treatment with baricitinib and topical corticosteroids was associated with a higher proportion of patients achieving clear or almost clear skin, according to data from the BREEZE-AD7 trial.
Abrocitinib meets primary, secondary endpoints in atopic dermatitis
Abrocitinib, in both 100 mg and 200 mg doses, significantly improved Investigator Global Assessment and Eczema Area and Severity Index-75 scores in patients with moderate to severe atopic dermatitis compared with placebo, meeting all endpoints in the phase 3 JADE MONO-1 study, which was presented at the European Academy of Dermatology and Venereology Congress.
Log in or Sign up for Free to view tailored content for your specialty!
Bermekimab improves all disease measures of atopic dermatitis in phase 2 study
Bermekimab, which neutralizes interleukin-1 alpha, improved all disease measures of atopic dermatitis, including a large reduction in pruritus, according to phase 2 trial results presented at the European Academy of Dermatology and Venereology Congress by Alice Gottlieb, MD, PhD, of Icahn School of Medicine at Mount Sinai.
Tralokinumab may neutralize IL-13 levels in atopic dermatitis
Interleukin-13 may be the central cytokine in the skin of patients with atopic dermatitis, and by blocking interleukin-13 with targeted therapies it is possible to block many key disease characteristics such as skin barrier deficiency, according to research presented at European Academy of Dermatology and Venereology Congress.
Recent updates in atopic dermatitis on tape strips, abrocitinib, Dupixent and more
Researchers have identified a minimally invasive technique using tape strips to study the phenotype and specific biomarkers in children with atopic dermatitis, in a popular story at Healio Dermatology, just in time for National Eczema Awareness Month.
Dupixent does not hamper patch testing in atopic dermatitis
Dupixent does not appear to exert an overarching dampening effect on patch test results, according to research published in Journal of the American Academy of Dermatology.
Patients overpay more for brand-name topical dermatologic drugs
Among topical dermatologic drugs, the mean overpayment for brand-name drugs was more than double that of generics, based on an analysis of claims data of privately insured individuals published in JAMA Dermatology.
Dermira begins phase 3 study of lebrikizumab in atopic dermatitis
Dermira announced treatment commencement in the first patient for a phase 3 study evaluating lebrikizumab in adult and adolescents with moderate to severe atopic dermatitis.
Tape strip approach identifies atopic dermatitis biomarkers in children
Researchers have found a way to evaluate the cutaneous biomarkers of atopic dermatitis via a minimally invasive method using tape strips, which may offer insight into tracking pediatric treatment responses in the future, according to recent findings published in JAMA Dermatology.
South Beach Symposium hosts renowned faculty, interactive learning
Dermatology is gearing up for the upcoming South Beach Symposium in Miami Beach, Florida, Feb. 6-9, 2020.
-
Headline News
Cannabis, hallucinogen use ‘historically high’ among adults in 2023
September 16, 20243 min read -
Headline News
Long-term exposure to air pollution may increase infertility risk in men
September 13, 20243 min read -
Headline News
Catching up on sleep over the weekend may have heart health benefits
September 16, 20242 min read
-
Headline News
Cannabis, hallucinogen use ‘historically high’ among adults in 2023
September 16, 20243 min read -
Headline News
Long-term exposure to air pollution may increase infertility risk in men
September 13, 20243 min read -
Headline News
Catching up on sleep over the weekend may have heart health benefits
September 16, 20242 min read